Is SpaceX's Starship a Threat to Rocket Lab Stock Now That It Has Reached Orbit?

SpaceX's Starship reached orbit and deployed 26 V3 Starlink satellites, raising the prospect that Starship could eventually free Falcon 9 capacity for third-party customers and pressure prices in Rocket Lab's target market. Rocket Lab's launch backlog nearly doubled to $940 million by June from roughly $476 million at year-end, but much of the growth is tied to the unflown Neutron rocket, whose first launch before end-2026 appears increasingly unlikely. Launch represented only $108 million, or 25%, of Rocket Lab's $434 million first-half revenue, while the company traded above 40x annualized revenue and generated negative free cash flow of about $188 million.

Analysis

The relevant valuation reset is not tied to Rocket Lab's current launch revenue; it is tied to the probability-weighted economics of Neutron. Greater Falcon 9 availability would compress the price umbrella precisely when Neutron needs high utilization to absorb its fixed launch infrastructure and development costs. That creates a double hit over the next 6-18 months: lower expected launch gross margin and a lower revenue multiple on an already cash-consuming business.

Rocket Lab's integrated spacecraft-plus-launch offering is the partial offset. Bundled missions can reduce customer integration risk and increase switching costs, making the company more defensible in national-security and bespoke constellation programs than in pure commercial launch procurement. The key distinction is whether new launch awards are tied to space-systems content; standalone Neutron commitments should be discounted until deposits, cancellation terms, launch cadence, and customer concentration are disclosed.

Near term, the initial orbital result is more strategically valuable to SpaceX than immediately disruptive to competitors: operational cadence, payload deployment reliability, and rapid reuse remain the gating variables. A successful sequence of Starship missions over the next 1-3 months would be the catalyst for Falcon 9 capacity-release expectations; a further Starship failure or regulatory pause would defer that pressure and could trigger a sharp RKLB relief rally. Consensus may be too linear in extrapolating a single flight, but it is likely underestimating the multiple risk if Neutron's first flight slips beyond 2026 while free cash flow burn persists.

Key Decisions for Investors

• Maintain an underweight/short bias in RKLB on 6-12 month horizon, preferably via a defined-risk put spread rather than outright short given high retail ownership and headline squeeze risk. Add only on rallies that are unsupported by a firm Neutron first-launch date; cover if management confirms 2026 flight readiness and secured launch deposits materially exceed expectations.
• Express the thesis as long RKLB space-systems execution versus short RKLB launch-optionality only if segment disclosure permits it; absent a separable instrument, use a small RKLB short sized to the risk that successful Neutron milestones re-rate the stock sharply.
• Set event alerts for Starship repeat-flight cadence, demonstrated satellite deployment, FAA licensing developments, and Falcon 9 commercial manifest availability over the next 90 days. Two or more successful operational Starship launches would strengthen the RKLB margin-compression case; a material Starship stand-down weakens it.
• Do not treat SPCX as directly investable based on the supplied ticker without confirming the listed security, capitalization, liquidity, and corporate relationship. For public-market exposure, wait for verified supplier or peer transmission rather than using an unverified symbol.